Hepatology at Mount Sinai: The present and the future

Citation
Pd. Berk et al., Hepatology at Mount Sinai: The present and the future, MT SINAI J, 68(2), 2001, pp. 88-95
Citations number
40
Categorie Soggetti
General & Internal Medicine
Journal title
MOUNT SINAI JOURNAL OF MEDICINE
ISSN journal
00272507 → ACNP
Volume
68
Issue
2
Year of publication
2001
Pages
88 - 95
Database
ISI
SICI code
0027-2507(200103)68:2<88:HAMSTP>2.0.ZU;2-A
Abstract
The Division of Liver Disease at Mount Sinai, now into its fifth decade, ha s evolved through two remarkable periods in its development and is on the c usp of a third exciting era. The first, extending from the division's creat ion in 1957 to the retirement in 1988 of its first division chief, Fenton S chaffner, was characterized by brilliant clinical and pathophysiologic insi ghts derived from the unique collaboration of Schaffner, a master clinician , with Hans Popper, a world renowned pathologist widely acknowledged as the father of the modern discipline of hepatology. The second, extending from the appointment in 1988 of Paul D. Berk as Schaffner's successor to the pre sent day, has witnessed enormous growth in the clinical and scientific acti vities of the division, together with the emergence of a world-class liver transplant program at Mount Sinai. During this recent period, an extensive program of formal clinical research was established; the basic research pro gram then expanded into the areas of hepatic transport, molecular virology, and the cellular and molecular pathogenesis of hepatic fibrosis; and both the clinical and research productivity of the division increased dramatical ly. A major undertaking, now in its second year, has been the creation of t he Center for the Study of Primary Biliary Cirrhosis; Mount Sinai has contr ibuted important advances toward the understanding of this disease. Funding for the Center, from the Artzt Family Foundation Trust, supports a series of interrelated basic studies on the immunology and pathobiology of the dis ease, as well as creation of a unique clinical database, a serum and tissue bank, and a program of clinical studies. This integration of basic and cli nical research in pursuit of new methods of diagnosis and treatment serves as a model for the division's continued leadership role.